Status:
APPROVED_FOR_MARKETING
An Expanded Access Program to Provide Nintedanib to Patients With Non-IPF ILD Who Have no Alternative Treatment Possibilities
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Lung Diseases, Interstitial
Eligibility:
All Genders
Brief Summary
This Expanded Access Program is intended to facilitate the availability of OFEV to patients suffering from non Idiopathic Pulmonary Fibrosis-Interstitial Lung Disease (non IPF-ILD) with a progressive ...
Eligibility Criteria
Inclusion
- None
Exclusion
- \- Patients who are eligible for and can participate in an ongoing non Idiopathic Pulmonary Fibrosis-Interstitial Lung Disease (non IPF-ILD) study will be excluded from participation in this Expanded Access Program (EAP).
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03843892
Last Update
December 10 2024
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Banner University Medical Center Tucson
Tucson, Arizona, United States, 85724
2
The Lung Research Center, LLC
Chesterfield, Missouri, United States, 63017
3
Glacier View Research Institute
Kalispell, Montana, United States, 59901
4
University of Rochester Medical Center
Rochester, New York, United States, 14559